OPKO Health, Inc. (Nasdaq: OPK) today announced its participation in the 3rd Annual Piper Sandler Obesity Symposium being held virtually on June 26, 2025. Management will be participating in a ...

These included the sale of its BioReference laboratory testing businesses, which focused on oncology and oncology-related ...

In this article, we will look at the 13 Best Long-Term Penny Stocks to Buy According to Analysts. What are the Fed’s Plans for 2025? On June 18, Société Générale’s Subadra Rajappa appeared on CNBC to ...

OPK's growth hinges on RAYALDEE and key partnerships, but rising competition and reliance on one drug pose risks.

Weston, Massachusetts Wednesday, June 11, 2025, 12:00 Hrs [IST] ...

OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE’s performance and strategic ...

OPKO Health bought ModeX in 2022 for its immunotherapy tech, with a focus on oncology and infectious diseases. At present, we cannot recommend OPKO stock to retail value investors.

Shares of Opko Health have decreased by 27.39% in the past year. An investor who bought shares of Opko Health at the beginning of the year would take a loss of $0.03 per share if they sold it today.

OPKO Health, Inc. OPK delivered a loss per share of 3 cents in the second quarter of 2023, narrower than the year-ago period’s loss of 14 cents.

OPKO Health ran into SEC-related issues in 2018 and its stock price has plummeted since. OPKO has a long history of operating losses, but it has the potential to change the situation.